INtervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer’s Symptomatic Expression (INCREASE), a Randomized Controlled Trial: Rationale, Study Design, and Protocol

Daniela C. Moga  
*University of Kentucky*, daniela.moga@uky.edu

Brooke F. Beech  
*University of Kentucky*

Erin L. Abner  
*University of Kentucky*, erin.abner@uky.edu

Frederick A. Schmitt  
*University of Kentucky*, fascom@uky.edu

Riham H. El Khouli  
*University of Kentucky*, elkhoulir@uky.edu

Follow this and additional works at: [https://uknowledge.uky.edu/pps_facpub](https://uknowledge.uky.edu/pps_facpub)

Right click to open a feedback form in a new tab to let us know how this document benefits you. See next page for additional authors

Repository Citation

Moga, Daniela C.; Beech, Brooke F.; Abner, Erin L.; Schmitt, Frederick A.; El Khouli, Riham H.; Martinez, Ashley I.; Eckmann, Lynne; Huffmyer, Mark; George, Rosmy; and Jicha, Gregory A., "INtervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer’s Symptomatic Expression (INCREASE), a Randomized Controlled Trial: Rationale, Study Design, and Protocol" (2019). *Pharmacy Practice and Science Faculty Publications*. 54.  
[https://uknowledge.uky.edu/pps_facpub/54](https://uknowledge.uky.edu/pps_facpub/54)

This Article is brought to you for free and open access by the Pharmacy Practice and Science at UKnowledge. It has been accepted for inclusion in Pharmacy Practice and Science Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
INtervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer's Symptomatic Expression (INCREASE), a Randomized Controlled Trial: Rationale, Study Design, and Protocol

Digital Object Identifier (DOI)
https://doi.org/10.1186/s13063-019-3993-0

Notes/Citation Information
Published in Trials, v. 20, issue 1, article no. 806.

© The Author(s). 2019

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors
Daniela C. Moga, Brooke F. Beech, Erin L. Abner, Frederick A. Schmitt, Riham H. El Khouli, Ashley I. Martinez, Lynne Eckmann, Mark Huffmyer, Rosmy George, and Gregory A. Jicha

This article is available at UKnowledge: https://uknowledge.uky.edu/pps_facpub/54
INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol

Daniela C. Moga1,2,3*, Brooke F. Beech3, Erin L. Abner2,3, Frederick A. Schmitt3,4, Riham H. El Khouli5, Ashley I. Martinez1, Lynne Eckmann6, Mark Huffmyer1,6, Rosmy George3 and Gregory A. Jicha3,4

Abstract

Background: The course of Alzheimer’s disease (AD) includes a 10–20-year preclinical period with progressive accumulation of amyloid β (Aβ) plaques and neurofibrillary tangles in the absence of symptomatic cognitive or functional decline. The duration of this preclinical stage in part depends on the rate of pathologic progression, which is offset by compensatory mechanisms, referred to as cognitive reserve (CR). Comorbid medical conditions, psychosocial stressors, and inappropriate medication use may lower CR, hastening the onset of symptomatic AD. Here, we describe a randomized controlled trial (RCT) designed to test the efficacy of a medication therapy management (MTM) intervention to reduce inappropriate medication use, bolster cognitive reserve, and ultimately delay symptomatic AD.

Methods/design: Our study aims to enroll 90 non-demented community-dwelling adults ≥ 65 years of age. Participants will undergo positron emission tomography (PET) scans, measuring Aβ levels using standardized uptake value ratios (SUVr). Participants will be randomly assigned to MTM intervention or control, stratified by Aβ levels, and followed for 12 months via in-person and telephone visits. Outcomes of interest include: (1) medication appropriateness (measured with the Medication Appropriateness Index (MAI)); (2) scores from Trail Making Test B (TMTB), Montreal Cognitive Assessment (MoCA), and California Verbal Learning Test (CVLT); (3) perceived health status (measured with the SF-36). We will also evaluate pre- to post-intervention change in: (1) use of inappropriate medications as measured by MAI; 2) CR Change Score (CRCS), defined as the difference in scopolamine-challenged vs unchallenged cognitive scores at baseline and follow-up. Baseline Aβ SUVr will be used to examine the relative impact of preclinical AD (pAD) pathology on CRCS, as well as the interplay of amyloid burden with inappropriate medication use.

Discussion: This manuscript describes the protocol of INCREASE (“INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression”): a randomized controlled trial that investigates the impact of deprescribing inappropriate medications and optimizing medication regimens on potentially delaying the onset of symptomatic AD and AD-related dementias.

(Continued on next page)
Background

Alzheimer’s disease (AD) is an important public health issue. Approximately 5.8 million Americans are currently living with AD [1], and this number is predicted to nearly triple by 2050 [2]. To forestall an impending crisis, the 2015 National Alzheimer’s Project Act (NAPA) report emphasized the need to identify effective prevention strategies to delay onset of symptomatic AD [3]. The biological disease course of AD has been elucidated, described as a 10–20-year preclinical period with progressive accumulation of amyloid plaques and neurofibrillary tangles, in the absence of symptomatic cognitive or functional decline [4]. The duration of this period is theoretically dependent on the rate of pathologic progression offset by compensatory mechanisms, collectively referred to as cognitive reserve (CR) [5]. Previous research has validated the importance of building and preserving CR to prolong this asymptomatic phase [5–7]. While much emphasis has been placed on developing and testing disease-modifying strategies targeting this preclinical phase of AD (pAD), little emphasis has been placed on currently available strategies targeting CR during pAD that may delay progression to the symptomatic stage of disease. Interventions designed to bolster CR (including aerobic exercise [8, 9], complex gameplay [10–12], diet [7, 13–16], and pharmacological interventions [17, 18]) have shown promise, but have not been proven to delay onset of symptomatic AD [5].

Medication therapy is a fundamental component of clinical care in older adults, but evidence suggests that pharmacotherapy in this population is often inappropriate [19]. Prescribing for older patients can be challenging due to factors such as age-related changes in adverse effect profiles and drug metabolism/catabolism, as well as the extensive use of polypharmacy to address multimorbidity [20, 21]. Lau et al. investigated medication use in older adults followed by National Institute on Aging-funded Alzheimer’s Disease Centers between 2005 and 2007, and estimated that 20% of those without dementia and 15% of those with dementia reported using at least one potentially inappropriate medication (PIM) as defined by the 2003 Beers criteria [19]. Another study found that frail elderly patients took an average of 15 medications (range 6 to 28) and experienced an average of 8.9 drug-related problems per patient (range 3 to 19), including inappropriate medication use and misuse and drug–drug and drug–disease interactions [22]. While these studies investigated PIM use on small, closely followed cohorts of patients, PIM use among older adults is widespread. A recently published paper used a nationally representative sample of the US older adults population and determined that 42.6% of older adult medication users reported at least one PIM as defined by the 2012 Beers criteria between 2006 and 2010 [23].

In a randomized controlled trial (RCT) using a patient-centered, clinician–pharmacist medication therapy management (MTM) intervention, we observed a 56% reduction in inappropriate anticholinergic drug use in older adults enrolled in the study [24]. These data document the efficacy of the MTM intervention to change inappropriate medication use and potentially delay dementia due to AD by maintaining CR. Based on our central hypothesis, as depicted in Fig. 1, interventions that deprescribe inappropriate medications and optimize treatment regimens for older adults with complex medical conditions may delay the substantial financial and societal impact of dementia due to AD by maintaining CR.

Here, we describe an RCT designed to expand the scope of the aforementioned pilot MTM intervention, from targeting only anticholinergic medications to targeting reduction in all inappropriate medications, bolster CR, and ultimately delay symptomatic AD. Finding the right balance between concomitantly treating several chronic conditions and avoiding medication-related negative effects is an important objective for healthcare providers, yet one that might be difficult to achieve [21, 25]. While clinicians regularly monitor and alter medication regimens when risks appear to outweigh benefits, the impact of inappropriate medication use is often not recognized by many healthcare providers. Interdisciplinary team approaches that focus on thorough medication reviews are designed to address this issue directly. The addition of a clinical pharmacist with extensive experience in conducting MTM reviews in older patients adds value for the brain health care provided to elderly at risk for PIM use. Our experience suggests that optimal medication management can be achieved through the development of a therapeutic triad including the clinician, pharmacist, and patient as outlined in Fig. 1.

Objectives

The INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression (INCREASE) study is designed to address two specific aims. The first aim is to conduct a 12-month RCT to evaluate the impact of a patient-centered, pharmacist–clinician team MTM intervention in deprescribing
unnecessary and inappropriate medication, and thus limiting their use. The second aim evaluates the association of amyloid burden with CR dysfunction (measured as cognitive reserve change score (CRCS)) to evaluate the efficacy of delaying symptomatic disease progression. We hypothesize that higher amyloid burden reduces CR, thus increasing susceptibility to “unmasking” of cognitive impairment by environmental stressors such as inappropriate medication use, which may hasten the onset of clinically evident cognitive impairment and dementia. Our objectives are as follows:

1. Assess the effectiveness of the MTM intervention in reducing inappropriate medication use over the study period as determined by the medication appropriateness index (MAI; Aim 1) [26]
2. Investigate the association of β-amyloid positron emission tomography (Aβ-PET) and MAI with CR, operationalized as CRCS = scopolamine challenged cognitive test performance versus unchallenged performance (Aims 1 and 2)
3. Investigate the effects of the MTM and changes in MAI on CRCS in participants that are Aβ-PET positive or negative over the one-year study period (Aims 1 and 2)

Methods/design
Study design synopsis
The INCREASE study is a single-site, randomized, placebo-controlled clinical trial currently being conducted at the University of Kentucky (UK). We plan to enroll 90 non-demented older adults. Participants will be randomly assigned to treatment with the MTM intervention or to continue with standard of care procedures. After enrollment, all participants are followed for 12 months. The UK Institutional Review Board (IRB) approved all study procedures and all participants provide informed consent to participate (see Additional file 1). In addition, the study is also monitored by an independent Data Safety and Monitoring Board (DSMB) consisting of a geriatrician, a geriatric pharmacist, and a trial statistician, as well as representatives from the National Institute on Aging. The DSMB meets every 6 months to review the progress of the study and evaluate participants’ safety. All serious adverse events are reported to the IRB and the DSMB within 24 h. Before implementation, protocol
modifications are approved by the UK IRB, and then reported to the DSMB and ClinicalTrials.gov.

**Study participants**
Participants will be recruited from Lexington, KY and the surrounding area, using IRB-approved media outlets, outreach activities, physicians engaged in the memory disorders clinic, and community physician or personal referrals. The study cohort consists of non-demented, community dwelling older adults (aged 65 years and over) who regularly take at least one medication included on the Beers 2015 list. The complete list of inclusion and exclusion criteria is detailed in Table 1.

**Data collection and study procedures**
Data collected from study participants are captured on paper source documents and entered and managed using electronic data capture tools hosted at UK [27, 28]. Research Electronic Data Capture (REDCap) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources. Study procedures are summarized in Fig. 2 and described in detail below.

**Scopolamine challenge**
Scopolamine patches are a widely used, safe, effective, Food and Drug Administration (FDA)-approved therapy for prevention of emesis and motion sickness in adults. FDA-approved dosing indicates a dose of 1.5 mg patch every 3 days. In the INCREASE study, patches are used for a more limited period of time, overnight prior to challenge cognitive testing (≥ 4 h) to allow 90% steady state blood levels of approximately 87 pg/mL for free scopolamine and 354 pg/mL for total scopolamine. The patches are removed immediately after testing is complete. Following patch removal, plasma levels decline in a log-linear fashion with an observed half-life of 9.5 h and normal cholinergic function is generally regained within 24 h of patch removal.

Scopolamine challenge has been used to assess cognitive vulnerability (i.e., CR) in published studies and has been shown to influence cognitive test performance at comparable subcutaneous (SQ) doses [29]. In addition, the patch is an easier and more tolerable delivery method than SQ dosing, which would require prolonged clinic visits (≥ 3 h to reach steady state with SQ dosing that could only be reliably administered in clinic).

The concept of the CRCS is designed to operationalize cognitive reserve as a quantifiable, objective score that can be compared over time irrespective of, but in addition to, longitudinal change in unchallenged cognitive test performance. We acknowledge that this calculation has not been utilized previously in studies but can

| Table 1 INCREASE study eligibility criteria |
|---------------------------------------------|
| **Inclusion criteria**                        |
| 1. Age ≥ 65 years                            |
| 2. Non-demented                              |
| 3. No previous reaction or contraindication to scopolamine patch, or medical condition warranting dose adjustment in scopolamine patch including but not limited to: open angle glaucoma, gastrointestinal or urinary outlet obstructions, seizures, or psychosis |
| 4. No contraindications to Aβ PET scan including hypersensitivity to PET ligand (florbetapir) or radiation exposure in the past year that would exceed acceptable safe annual exposure in combination with the Aβ PET |
| 5. Medically stable and able to complete all study activities, in the opinion of the investigator |
| 6. Reporting at least one potentially inappropriate medication as listed in the Beers 2015 criteria |
| 7. Living in the community                    |
| 8. Able to identify a study partner who will drive the participant to and from the scopolamine-challenged visits |
| 9. Willing to participate in this intervention study |
| **Exclusion criteria**                         |
| 1. Allergy or known intolerance to scopolamine patches |
| 2. Narrow-angle glaucoma                      |
| 3. Difficulty swallowing                      |
| 4. Stomach or bowel problems (e.g., blockage, muscle weakness, ulcerative colitis) |
| 5. Myasthenia gravis                          |
| 6. Blockage of the urinary tract               |
| 7. Seizures                                   |
| 8. Psychosis                                  |
| 9. Contraindications to Aβ PET scan including hypersensitivity to PET ligand (florbetapir) or radiation exposure in the past year that would exceed acceptable safe annual exposure in combination with the amyloid β PET |

*PET positron emission tomography, Aβ amyloid beta*
be deduced from published data on scopolamine challenge in other paradigms as challenged vs unchallenged cognitive test scores. A difference equal to 0 would indicate healthy cognitive reserve reflective of the participant’s ability to tolerate the patch without diminution in cognitive test scores, whereas change scores lower than 0 (and in excess of measurement error) would indicate anticholinergic sensitivity as a surrogate quantitative measure of cognitive reserve [29].

Randomization and blinding
Randomization is stratified by quantitative Aβ standardized uptake values ratios (SUVr), normalized to cerebellum, as determined following the PET scan: SUVr < 1.2, 1.2 ≤ SUVr < 1.4, and SUVr ≥ 1.4 [30, 31]. Utilization of these three strata (each stratum includes approximately one-third of the study population) ensures that amyloid burden will be equally distributed across the treatment groups. Within SUVr strata, participants are randomized to the MTM intervention or standard of care with equal probability. Randomization occurs on the third study visit (Table 2). Consecutive treatment assignments are sealed in opaque envelopes by the study statistician and opened by the study coordinator following the screening visit, PET scan, and baseline cognitive assessments.

PET scan
Aβ-PET imaging is currently FDA-approved for the detection of cerebral amyloid deposition in patients with dementia. It does not currently have an indication for the detection of cerebral amyloidosis in patients that do not have dementia. With these caveats in mind, Aβ-PET imaging has been reliably used to detect pAD across numerous studies, detecting cerebral amyloidosis in approximately one-third of the cognitively normal population over the age of 65 years [4, 32]. Current clinical use of Aβ-PET scans relies on a subjective determination of dichotomous presence vs absence of radiolabel binding to cortical regions, which is subject to multiple sources of error, including visual color discrimination and the experience of the interpreting radiologist. Quantitative SUVR determinations are more precise and allow for the specification of amyloid burden as a continuous variable that will be leveraged in the current study allowing associations with cognitive test performance and CRCS to be examined secondarily across the continuum of cerebral amyloid burden that characterizes pAD [33].

For each scan, the participant receives a single intravenous administration of approximately 370 MBq (10 mCi) of flurbetapir F 18 (fast intravenous push). The injection of the imaging agent is followed by a saline flush. After an uptake period of 50 min, participants will be positioned in a head
stabilization unit designed for PET/CT scanners. All PET/CT scans are performed on a Siemens Biograph TruePoint 6-slice (Siemens Healthcare, Erlangen, Germany). Low resolution CT images of the head will be acquired (120 kVp, FOV 50 cm, pitch 0.55, 0.5 s rotation time, slice thickness 4 mm, care dose). PET images of the brain are then collected for a 20-min, 3D emission scan. The emission images will be reconstructed using 256×256 matrix and all pass filter. Injected dose, time of injection, residual radiotracer within the syringe after injection, and patient weight and height are recorded to be used for the standardized uptake value calculation based on the following equation:

\[
SUVR = \frac{\text{uptake (kBq/mL)}}{\text{injected dose (kBq)/patient weight (g)}}
\]

Image analysis will be done using dedicated PET/CT image analysis software, Mirada (version XD3, Mirada Medical Ltd, New Road, Oxford, UK). Multi-planar reconstruction (MPR) of the axial images of both PET and CT datasets as well PET/CT fused images are reconstructed in the sagittal and coronal planes. Change in brain amyloid burden (as assessed by florbetapir binding and measured by mean cortical standardized uptake value ratio (SUVR)) will be analyzed. Total brain SUVr is calculated as described previously by the AV45-A11 Study Group [33]. Specifically, multiple volumes of interests (VOI) will be placed on different parts of the cortex (frontal, parietal, temporal, occipital, precuneus, posterior cingulate regions) as well as the pons and cerebellum. SUV ratios for each VOI will be generated using the cerebellum and pons (SUVR denominators).

### Study intervention

As the MTM intervention is educational and delivered in person, complete blinding of treatment assignment is not possible. However, we are taking the following steps to minimize potential bias and achieve the maximum level of blinding possible by this design: (1) when reviewing the medication list prior to the intervention, the study coordinator, study pharmacist, and clinician are unaware of the group allocation; (2) data analysis will be blinded to the intervention.

At enrollment, each participant is asked to bring all prescription and non-prescription medications and supplements they currently use. In a face-to-face interview, study personnel collect information on treatment indication, duration, dose and mode of administration, and adherence [34]. If participants report any adverse effects, study personnel record information on the suspected medication, symptomatology, and subsequent treatment modification (whether initiated by the participant or a healthcare provider) [34].

The study pharmacist then reviews the information and prepares prioritized written recommendations as follows: (1) a list of potentially inappropriate medications taken by the patients that are included in, but are not limited to, the 2015 Beers criteria [35] (the

| Procedure                      | Screening | Baseline cognitive testing | Month 3 | Month 6 | Month 9 | End-of-study cognitive testing |
|--------------------------------|-----------|---------------------------|---------|---------|---------|-------------------------------|
| Study week                    | –5 ± 2 weeks | –4 ± 1                    | 0 ± 1       | 13 ± 1   | 26 ± 1   | 39 ± 1                       |
| Demographics                  | X         | X                         | X        | X       | X       | X                            |
| Health history                | X         | X                         | X        | X       | X       | X                            |
| Medication review             | X         | X                         | X        | X       | X       | X                            |
| NAART                         | X         |                           |          |         |         | X                            |
| TMTB                          | X         | X                         | X        |         |         | X                            |
| CVLT                           | X         | X                         | X        |         |         | X                            |
| MoCA                          | X         | X                         | X        |         |         | X                            |
| SF-36                          | X         |                           |          |         |         | X                            |
| ECG                            | X         |                           |          |         |         | X                            |
| Physical exam                 | X         |                           |          |         |         | X                            |
| Neurological exam             | X         |                           |          |         |         | X                            |
| Gait and balance              | X         | X                         | X        | X       | X       | X                            |
| Aβ-PET imaging                | X         |                           |          |         |         | X                            |
| MTM intervention              | X         | X                         | X        | X       |         | X                            |
| Telephone follow-up           | X         | X                         |          |         |         | X                            |

**NAART** North American Adult Reading Test, **TMTB** Trail Making Test B, **CVLT** California Verbal Learning Test, **MoCA** Montreal Cognitive Assessment, **SF-36** Short-Form 36, **ECG** electrocardiogram, **Aβ** amyloid beta, **PET** positron emission tomography, **MTM** medication therapy management
“problem list”); (2) a proposed action for each medication in the problem list (discontinuation, treatment modification (including suggested alternative or dose change), or treatment continuation when medically necessary); and (3) proposed action for any other prescription or non-prescription medication or supplement taken by the participant that might be inappropriate and/or unnecessary. Where appropriate, the proposed alternatives include medications suggested in the 2015 Beers 2015 criteria as “Alternative medications for medications in the use of high-risk medications in the elderly and potentially harmful drug-disease interactions in the elderly quality measures” [35, 36]. All study participants, regardless of their group assignment, are provided with educational materials focused on appropriate medication use and being an active participant in their healthcare team: “Avoiding overmedication and harmful drug reactions” (www.HealthinAging.org), “Ten medications older adults should avoid or use with caution” (www.HealthinAging.org), and “Be an active member of your health care team” (https://www.fda.gov/drugs/resources-you/be-active-member-your-health-care-team-article).

Throughout study follow-up, the control group receives standard medical care from their primary care providers. The MTM intervention is based on patient-centered principles by addressing the specific needs of each individual patient, taking into consideration the individual patient’s preferences and values, and by empowering the patient to take responsibility and fully participate in the decision-making process as an equal team player [37–39]. Following the preliminary medication review described above and the communication between the pharmacist and the clinician, those randomized to the MTM intervention meet with the pharmacist–clinician team during case conferences to discuss the problem list and decide on final recommendations for discontinuation or change related to inappropriate medications. The final recommendations and their rationale, along with general medication information, are discussed by the team with the participant. For the participants included in the MTM intervention group, the written recommendations and proposed changes are shared with their primary care providers, who are consulted on the best approach to improve outcomes. Although recommendations are made, the study team cannot force changes. For the duration of the study, the study coordinator contacts the participant every 3 months to follow-up on the proposed changes during the MTM intervention and to determine the need for additional pharmacist evaluations of newly prescribed medications.

The detailed schedule of study procedures by specific visits is included in Table 2 and Fig. 3.

Study outcomes
Study outcomes are summarized in Table 3 and described in detail below.

Medication Appropriateness Index (MAI)
The MAI provides explicit instructions and examples to guide rating of medications as “appropriate”, “marginally appropriate”, or “inappropriate” based on ten criteria [26]. MAI assessments made by a clinical pharmacist and a physician demonstrated high inter- and intra-rater reliability (kappa = 0.83 and 0.92, respectively) [26]. While our focus is on medications considered potentially inappropriate by the 2015 Beers criteria, all medications reported by the participants at baseline and follow-up visits are evaluated by the study pharmacist in collaboration with the study clinician. Medication appropriateness is assessed by the study pharmacist in a blinded manner, prior to randomization for the baseline assessment, and without knowledge of the group assignment at the end of the study visit. We will also measure the reduction in the number of PIMs from baseline to the end of the study.

Cognitive reserve
We operationalize a residual measure of CR utilizing sequential cognitive testing under a scopolamine challenge, followed after 4 weeks by unchallenged cognitive testing, as described in the Scopolamine challenge section. The difference in challenged and unchallenged performance is calculated as the cognitive reserve change score (CRCS) at baseline and the end of study (EOS). This novel method of operationalizing a cognitive reserve measure with an anticholinergic challenge has the added benefit of minimizing learning effects that may arise as a result of the sequential cognitive testing.

Several cognitive measures, including Trail Making Test B (TMTB) [40, 41], Montreal Cognitive Assessment (MoCA) [42, 43], and California Verbal Learning Test (CVLT) [44], will be used when calculating CR, each highlighting different components of cognition. All the tests are also available in multiple validated test versions, which can limit learning effects from repeated testing [45, 46]. TMTB was selected as the primary outcome measure based on our previously published work on inappropriate medication use in older adults [35, 47]. Our statistical considerations and power analysis are based on the data from this work. TMTB measures higher order executive function, which is a prime target for cognitive changes resulting from PIM use [35, 47], and has been shown to be a sensitive measure of cognitive decline in PdD [48]. MoCA and CVLT were chosen as global cognition and memory measures (respectively) to allow comparison to other cohorts, including the longitudinal cohort at the Alzheimer’s Disease Center at University of Kentucky (UK-ADC) [42, 43].
Perceived health status
Change in perceived health status is measured to estimate the overall impact of the MTM intervention using the Short Form Health Survey (SF-36) at baseline and EOS. The SF-36 is a validated generic instrument that evaluates eight health concepts categorized into three major health attributes: (1) functional status (i.e., physical functioning, social functioning, role limitations due to physical problems, role limitations due to emotional problems); (2) well-being (mental health, vitality, bodily pain); and (3) general health perception (an overall evaluation of health) [49]. Previous research has reported that the SF-36 correlates with Sickness Impact Profile scores, a more thorough health status evaluation that could not be conducted feasibly in this trial [50, 51].

Table 3 Study outcomes

| Study outcomes | Primary | Medication appropriateness | MAI | Change from pre- to post-intervention | Executive function | TMTB | CRS: difference in scopolamine-challenged and unchallenged z-scores | Secondary | Global cognition | MoCA | Memory | CVLT | Perceived health status | SF-36 | Change from pre- to post-intervention |
|----------------|--------|-----------------------------|-----|--------------------------------------|-------------------|-----|---------------------------------------------------------------|----------|------------------|-----|--------|------|----------------------|-------|-------------------------------------|
|                |        | MAI                         |     |                                      |                   |     |                                                               |          |                  |     |        |      | Medication appropriateness index, TMTB Trail Making Test B, CVLT California Verbal Learning Test, MoCA Montreal Cognitive Assessment, SF-36 Short-Form 36 |
intervention group vs no change in the control group. We will need 17 participants in each group to detect this difference with 80% power at a significance level (α) of 0.05. As we expect the effect of the intervention to be even greater for those with pAD, we have based the power analysis at a mean difference of 1.5 in MAI. Based on this assumption, for the subgroup analysis of subjects with pAD, we would need nine participants per group to detect this difference with 80% power at α = 0.05, and 11 per group to detect this difference with 90% power. These MAI effect sizes are rather conservative as previous studies show that medication reconciliation interventions can determine a mean MAI change ranging between 1.9 and 17 [52].

Our previous studies have demonstrated that cognitively intact older adults who used anticholinergic medications did not show learning effects for TMTB (i.e., scores remained unchanged over time), while nonusers showed a statistically significant improvement after 6 years [53]. Our findings are consistent with another study in younger adults that identified reduced psychomotor and executive function in participants treated with 0.2 mg scopolamine subcutaneously (± 0.75 and ± 0.50 standard deviations, respectively) [54]. Since TMTB involves both psychomotor and executive function, it is reasonable to assume that we will observe deficits on this instrument in non-demented older adult participants challenged with scopolamine. Thus, we will compute age- and education-adjusted TMTB z-scores based on normative data for cognitively intact older adults [41]. Assuming our scopolamine challenge will induce deficits in cognitively intact older adults at least at the levels reported in younger adults, we will need 32 participants per group to detect a 0.50 SD improvement in the CRCS z-score with 80% power at α = 0.05, and 14 per group to detect a 0.75 SD improvement with 80% power in participants with pAD.

Analysis strategy
To examine the effect of the intervention on medication appropriateness, we will perform analysis of covariance (ANCOVA), with the dependent variables being the difference between outcome measures at baseline and EOS, and the baseline measurement included as a covariate. Because the SF-36 does not produce a single overall measure and to reduce the number of comparisons, multivariate analysis of covariance (MANCOVA) will be used to simultaneously estimate the effect of the MTM intervention on the eight SF-36 health concepts. There are no planned interim analyses for INCREASE. Adverse events related to study participation are monitored by the UK IRB and the study DSMB and reported according to Federal regulation. At the minimum, the DSMB meeting is every 6 months.

Discussion
The current paper describes the rationale and protocol of the INCREASE study, a single-center RCT designed to investigate (1) the impact of a patient-centered, pharmacist-clinician team MTM intervention in reducing unnecessary and inappropriate medication use, and (2) the interplay of deprescribing inappropriate medication and amyloid burden on cognitive reserve deficits and decline. Combining state-of-the-art detection of pAD through Aβ-PET with a unique patient-centered interdisciplinary MTM intervention is highly innovative, and directly translatable to clinical practice.

We hypothesize that the burden of pAD pathology will dampen CR, increasing susceptibility to “unmasking” of dementia symptoms by environmental stressors such as inappropriate medication use. In addition, by reducing CR, inappropriate medication use may hasten the onset of clinically evident dementia, prolonging the symptomatic phase of disease where health care costs are maximally incurred. Our preliminary work demonstrates that such impact is both feasible and achievable through practical establishment of procedures and policies designed to evaluate and reduce inappropriate medication use in older adults. The INCREASE study directly addresses a fundamental gap in existing knowledge on how MTM interventions may prove beneficial in delaying AD onset, shortening the overall duration of symptomatic disease expression, and reducing healthcare costs.

Some potential limitations of the current study lie in the use of the CRCS measure, which has not been previously validated. This concept, however, is based on scientific data that demonstrate that such a measure exists [29], that it can be calculated easily, and that such an approach can move to the field of intervention in pAD forward [32]. Furthermore, its calculation is in line with other methods being developed to operationalize CR [55]. Regardless, the INCREASE study is strengthened by preliminary interventional data demonstrating that our primary outcome measure of MAI change is achievable within the proposed study design. The potential economic health impact of the study warrants exploration of this approach to the preclinical phase of AD and reducing the duration of symptomatic disease, where most health expenditures lie.

At the time of writing, recruitment and enrollment are ongoing and are expected to be completed by early 2020. Follow-up measures will be completed by early 2021 with results expected to become available in late 2021.

Trial status
- Current protocol version number and date: version 6, dated August 27, 2019
Date recruitment began: March 23, 2017
Approximate date when recruitment will be completed: March 31, 2020

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13063-019-3993-0.

Additional file 1. SPIRIT 2013 checklist.

Abbreviations
AD: Alzheimer’s disease; ANCOVA: Analysis of covariance; Aβ: Amyloid β; CR: Cognitive reserve; CRCS: Cognitive Reserve Change Score; CT: Computed tomography; CVLT: California Verbal Learning Test; ECG: Electrocardiogram; FDA: Food and Drug Administration; INCREASE: Intervention for Cognitive Reserve Enhancement for delaying the onset of Alzheimer’s Symptomatic Expression; IRB: Institutional review board; MAI: Medication Appropriateness Index; MoCA: Montreal Cognitive Assessment; MPR: Multi-planar reconstruction; MTM: Medication therapy management; NAART: North American Adult Reading Test; NAPA: National Alzheimer’s Project Act; PdAD: Preclinical Alzheimer’s disease; PET: Positron emission tomography; PIM: Potentially inappropriate medications; RCT: Randomized controlled trial; REDCap: Research electronic data capture; SD: Standard deviation; SF-36: Short Form-36; SUVr: Standard uptake value ratio; TMTB: Trail Making Test B

Acknowledgements
The authors would like to thank the participants and their study partners, without whom this study would not have been possible. In addition, the authors would like to thank Dr. Shani Bardach and Mr. Hardin Stevens for supporting the recruitment efforts for the study, and Mrs Teri Timmons for providing administrative support for the study.

Authors’ contributions
DCM serves as co-principal investigator and designed the study, obtained funding, currently provides oversight for data collection, and drafted the manuscript. DCM will also oversee the statistical analysis and interpret the study results. BFB was involved in the collection of patient data, performed cognitive, gait and balance testing, and drafted the manuscript. ELA was involved in the design of the study, prepared the randomization envelopes, will be conducting the statistical analysis and the interpretation of the results, and was a major contributor in writing the manuscript. FAS was involved in the design of the study, will help with the interpretation of the results, and was a major contributor in writing the manuscript. RHEK was involved in the design of the study, is evaluating the PET scans, will help with the interpretation of the results, and was a major contributor in writing the manuscript. AIM is involved in the collection of patient data, performed MTM interventions, and helped to draft the manuscript. MH is involved in the collection of patient data, performs MTM interventions, and helped to draft the manuscript. GAJ will also oversee the statistical analysis and interpretation of the study results. All authors read and approved the final manuscript. No professional writers were involved in the writing of the manuscript.

Funding
This study is supported by an unrestricted grant from the National Institutes of Health/National Institute on Aging (R01 AG054130). Additional support was provided by the University of Kentucky Center for Clinical and Translational Sciences (UL1TR000117).

Availability of data and materials
In accord with Federal regulations, this trial is registered with ClinicalTrials.gov and all raw data, stripped of identifiers, will be made available to interested parties and researchers with submission of written request to the study PI, not sooner than one year after acceptance and publication of the primary manuscript. There will be no charge for release of the dataset.

Ethics approval and consent to participate
The study was approved by the Institutional Review Board at University of Kentucky (IRB #43239) and all participants provide signed informed consent for participation.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
2 Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, USA.
3 Sanders-Brown Center on Aging, Lexington, KY, USA.
4 Department of Neurology, College of Medicine, University of Kentucky, Lexington, KY, USA.
5 Department of Radiology, College of Medicine, University of Kentucky, Lexington, KY, USA.
6 PRO2RX LLC Pharmacy Consulting Services, Lexington, KY, USA.

Received: 6 October 2019 Accepted: 11 December 2019
Published online: 30 December 2019

References
1. Alzheimer’s Association. Alzheimer’s facts and figures. 2019. https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf. Accessed 1 Oct 2019.
2. Hebert LE, et al. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001;15(4):169–73.
3. Changing the trajectory of Alzheimer’s disease: How a treatment by 2025 saves lives and dollars. 2015. https://www.alz.org/media/documents/changing-the-trajectory-r.pdf. Accessed 1 Oct 2019.
4. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):290–92.
5. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012;11(1):1006–12.
6. Charlesworth CJ, et al. Polypharmacy among older adults aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):888–95.
7. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009;66(10):1210–5.
8. Angevaren M, Audefkimpe G, Verhaar HJJ, Alemann A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2008(3):CD005381. https://doi.org/10.1002/14651858.CD005381.pub3
9. Kramer AF, et al. Fitness, aging and neurocognitive function. Neurobiol Aging. 2005;26(Suppl 1):244–7.
10. Fabiani M, Buckley J, Gratton G, Coles MGH, Donkin E. The training of complex task performance. Acta Psychol. 1989;71:259–99.
11. Gopher D, Well M, Bareket T. Transfer of skill from a computer game trainer to flight. Hum Factors. 1994;36(3):387–405.
12. Oreill M, Sahakian B. Education and dementia. BMJ. 1995;310(6985):951–2.
13. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol. 2009;5(3):140–52.
14. Gillette Guyneton S, et al. JANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging. 2007;11(2):132–52.
15. Kang JR, et al. A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med. 2006;166(2):2462–8.
16. Yaffe K, et al. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology. 2004;63(9):1705–7.
17. Moulder KL, et al. Dominantly Inherited Alzheimer Network facilitating research and clinical trials. Alzheimers Res Ther. 2013;5(5):48.
18. Sperling RA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(28):228fs13.

19. Lau DT, et al. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord. 2010;24(1):56–63.

20. By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers criteria(8) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.

21. Steinman MA, et al. How to use the American Geriatrics Society 2015 Beers criteria-a guide for patients, clinicians, health systems, and payors. J Am Geriatr Soc. 2015;63(12):e1-e7. https://doi.org/10.1111/jgs.13701. Epub 2015 Oct 8.

22. Farrell B, Szeto W, Shamji S. Drug-related problems in the frail elderly. Can Fam Physician. 2011;57(2):168–9.

23. Davidoff A, et al. Prevalence of potentially inappropriate medication use in older adults using the 2012 Beers criteria. J Am Geriatr Soc. 2015;63(3):486–500.

24. Moga DC, et al. Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden. Alzheimers Res Ther. 2017;9(1):36.

25. Steinman MA. Polypharmacy and the balance of medication benefits and risks. Am J Geriatr Pharmacother. 2007;5(4):314–6.

26. Hanlon JT, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.

27. Harris PA, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.

28. Snyder PJ, et al. Microdosing of scopolamine as a cognitive stress test; rationale and test of a very low dose in an at-risk cohort of older adults. Alzheimers Dement. 2014;10(2):262–7.

29. Clark CM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83.

30. Fleisher AS, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404–11.

31. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2014;28(3):295–301.

32. By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46. https://doi.org/10.1111/jgs.13702. Epub 2015 Oct 8.

33. Hanlon JT, Semla TP, Schmader KE. Alternative medications for medications in older adults. J Am Geriatr Soc. 2015;63(12):e1-e8. https://doi.org/10.1111/jgs.13807. Epub 2015 Oct 8.

34. Steinman MA, et al. How to use the American Geriatrics Society 2015 Beers criteria-a guide for patients, clinicians, health systems, and payors. J Am Geriatr Soc. 2015;63(12):e1-e7. https://doi.org/10.1111/jgs.13701. Epub 2015 Oct 8.

35. Hanlon JT, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428–37.

36. Bottiggi KA, et al. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. Am J Geriatr Psychiatry. 2007;15(4):357–9.

37. Jicha GA, Carr SA. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis. 2010;19(1):253–72.

38. Stewart AL, Ware JE Jr, Brook RH. Advances in the measurement of functional status: construction of aggregate indexes. Med Care. 1981;19(5):473–88.

39. Hanlon JT, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65(12):1304–10.

40. Weinberger M, et al. An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc. 1991;39(7):691–4.

41. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893–900.

42. Bottiggi KA, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006;14(11):980–4.

43. Fredrickson A, et al. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Hum Psychopharmacol. 2008;23(5):425–36.

44. Stern Y, et al. Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2018. https://doi.org/10.1016/j.jalz.2018.07.219.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.